|
Mar 27
|
PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update
|
|
Mar 27
|
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
|
|
Mar 20
|
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results
|
|
Mar 13
|
The 3 Most Undervalued Biotech Stocks to Buy in March 2024
|
|
Mar 13
|
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune®
|
|
Jan 16
|
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference
|
|
Jan 2
|
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy
|
|
Dec 4
|
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
|
|
Nov 28
|
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer
|
|
Sep 6
|
PDS Biotech to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
|
|
Sep 6
|
PDS0202 Universal Influenza Preclinical Ferret Data to be Presented in Oral Lecture at 9th ESWI Conference
|
|
Aug 7
|
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2023 Financial Results
|
|
May 25
|
PDS Biotech Announces Interim Data Demonstrates 12-Month Survival Rate of 87% with PDS0101 in Combination with KEYTRUDA® (pembrolizumab) for Head and Neck Cancer Patients
|